These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 18157732)

  • 1. The burden of rheumatoid arthritis and access to treatment: health burden and costs.
    Lundkvist J; Kastäng F; Kobelt G
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S49-60. PubMed ID: 18157732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The burden of rheumatoid arthritis and access to treatment: determinants of access.
    Lundqvist J; Kastäng F; Kobelt G; Jönsson B
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S87-93. PubMed ID: 18157560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies.
    Jönsson B; Kobelt G; Smolen J
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S61-86. PubMed ID: 18097697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments.
    Kobelt G; Jönsson B
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():95-106. PubMed ID: 18157559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
    Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
    Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient access to rheumatoid arthritis treatments.
    Jönsson B
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S35-8. PubMed ID: 18157679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
    van den Hout WB; Goekoop-Ruiterman YP; Allaart CF; de Vries-Bouwstra JK; Hazes JM; Kerstens PJ; van Zeben D; Hulsmans HM; de Jonge-Bok JM; de Sonnaville PB; Dijkmans BA; Breedveld FC
    Arthritis Rheum; 2009 Mar; 61(3):291-9. PubMed ID: 19248130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The burden of rheumatoid arthritis. Based on a presentation by Frederick Wolfe, MD.
    Am J Manag Care; 1999 Sep; 5(14 Suppl):S852-9; discussion S866-9. PubMed ID: 10621071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis.
    Andrews G; Simonella L; Lapsley H; Sanderson K; March L
    J Rheumatol; 2006 Apr; 33(4):671-80. PubMed ID: 16541479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic costs of diabetes in the U.S. In 2007.
    American Diabetes Association
    Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The burden of rheumatoid arthritis and access to treatment: a medical overview.
    Smolen J; Aletaha D
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S39-47. PubMed ID: 18157733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The societal burden of osteoporosis in Sweden.
    Borgström F; Sobocki P; Ström O; Jönsson B
    Bone; 2007 Jun; 40(6):1602-9. PubMed ID: 17433804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the cost of epilepsy in Europe: a review with economic modeling.
    Pugliatti M; Beghi E; Forsgren L; Ekman M; Sobocki P
    Epilepsia; 2007 Dec; 48(12):2224-33. PubMed ID: 18088267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
    Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
    Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheumatoid arthritis.
    Sutor SM; Gricar JA; Cave DG
    Manag Care Interface; 1999 Jun; 12(6):51-3. PubMed ID: 10538460
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies.
    Lipsky PE; Kavanaugh A
    Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():41-4. PubMed ID: 10646490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis?
    March L; Lapsley H
    Best Pract Res Clin Rheumatol; 2001 Mar; 15(1):171-85. PubMed ID: 11358421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.